Nuevocor, a biotechnology company that develops therapies for cardiomyopathies, has appointed Monica Shah, MD, as chief medical officer.
Dr. Shah is a heart failure and transplant cardiologist with more than 20 years of experience in cardiovascular medicine and drug development, according to an April 28 news release from Nuevocor.
In the role, Dr. Shah will lead Nuevocor’s global clinical development and medical affairs. The company is currently preparing to initiate a first-in-human clinical study of NVC-001 in patients with LMNA-associated dilated cardiomyopathy, the release said.
Dr. Shah most recently served as chief medical officer of CTI Clinical Trial & Consulting, overseeing medical strategy across clinical programs including rare disease, gene therapy and cardiovascular indications, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.